Beacon Biosignals, a computational neurodiagnostics and electroencephalogram analytics company, completed the acquisition of Dreem, a pioneer in at-home sleep monitoring. Financial terms were not disclosed. "We are excited to announce the acquisition of Dreem, which marks a significant step forward in our mission to rapidly advance precision medicines for the brain. It has always been our vision to expand clinical-grade brain monitoring to usher in the era of precision therapies in sleep medicine and the most difficult-to-treat neuropsychiatric conditions. There's no substitute for recording directly from the brain, and the Dreem device will accelerate Beacon's scale-up of validated sleep endpoints across a wide range of clinical trials," Jacob Donoghue, Beacon Biosignals CEO.